Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial

• Main Authors: Scagliotti G.V., Krzakowski M., Szczesna A., Strausz J., Makhson A., Reck M., Wierzbicki R.F., Albert I., Thomas M., Miziara J.E.A., Papai Z.S., Karaseva N., Thongprasert S., Portulas E.D., Von Pawel J., Zhang K., Selaru P., Tye L., Chao R.C., Govindan R.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.ncbi.nlm.nih.gov/pubmed/22564989; http://www.scopus.com/inward/record.url?eid=2-s2.0-84863936062&partnerID=40&md5=71f3fd5a13e1ebc6cc7d358ea110206a; http://cmuir.cmu.ac.th/handle/6653943832/3848
• Institution: Chiang Mai University

Purpose: Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor growth, angiogenesis, and metastasis. This phase III trial investigated overall survival (OS) f...